The Latest Breaking News from CRL

Amid market turbulence and policy shifts, do two of the S&P 500’s steepest decliners, DECK and CRL, offer deep value or signal deeper trouble ahead?

As Charles River Laboratories has underperformed its industry peers recently, analysts remain cautious about the stock’s prospects.

Charles River Laboratories has lagged behind the broader market over the past year, with Wall Street analysts maintaining a cautious outlook on its future performance.

Charles River Laboratories will release its fourth-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Charles River Laboratories has underperformed the healthcare sector over the past year, and analysts are cautious about the stock’s prospects.

Charles River Laboratories underperformed the broader market over the past year, and Wall Street analysts remain cautious about the stock’s prospects.

Charles River Laboratories is expected to announce its third-quarter results next month, and analysts predict a double-digit decline in the company’s bottom-line figure.

Charles River Laboratories underperformed the Dow recently, but Wall Street analysts remain moderately optimistic about the stock’s prospects.

Charles River Laboratories underperformed the broader market over the past year, and Wall Street analysts remain moderately optimistic about the stock’s prospects.

Charles River Laboratories is poised to release its second-quarter earnings next month, and analysts expect a double-digit earnings dip.

Wayne Brown vowed to stop doing new roading projects until existing ones were finished, and to unclog the city centre's streets - but now finds himself enthusiastically backing a new period of upheaval for the key crossroad of Victoria St.